Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2

Journal of Clinical Oncology

Volumn 22, Issue 5, 2004, Pages 785-794

  Herbst, Roy S ^a   Giaccone, Giuseppe ^b   Schiller, Joan H ^b   Natale, Ronald B ^b   Miller, Vincent ^b   Manegold, Christian ^b   Scagliotti, Giorgio ^b   Rosell, Rafael ^b   Oliff, Ira ^b   Reeves, James A ^b   Wolf, Michael K ^b   Krebs, Annetta D ^b   Averbuch, Steven D ^b   Ochs, Judith S ^b   Grous, John ^b   Fandi, Abderrahim ^b   Johnson, David H ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; GEFITINIB; PACLITAXEL; PLACEBO; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SAFETY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SKIN TOXICITY; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; AGED; CANCER STAGING; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; REFERENCE VALUE; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUINAZOLINES; REFERENCE VALUES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 1542713370     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.215     Document Type: Article

References (34)

1. Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000: The global picture. Eur J Cancer 37:S4-S66, 2001 (suppl 8)
2. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
3. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
4. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82:241-250, 1999
5. Nakagawa K, Tamura T, Negoro S, et al: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumours. Ann Oncol 14:922-930, 2003
6. Ranson M, Hammond LA, Ferry D, et al: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: Results of a phase I trial. J Clin Oncol 20:2240-2250, 2002
7. Herbst RS, Maddox AM, Rothenberg ML, et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 20:3815-3825, 2002
8. Baselga J, Rischin D, Ranson M, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302, 2002
9. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
10. Natale RB, Skarin A, Maddox A-M, et al: Improvement in symptoms and quality of life for advanced non-small-cell lung cancer patients receiving ZD1839 ('Iressa') in IDEAL 2. Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1167)
11. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
12. Massarelli E, Andre F, Liu DD, et al: A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39:55-61, 2003
13. Ciardiello F, Caputo R, Bianco R, et al: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063, 2000
14. Sirotnak FM, Zakowski MF, Miller VA, et al: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892, 2000
15. Miller VA, Johnson DH, Krug LM, et al: Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol 21:2094-2100, 2003
16. Giaccone G, Herbst RS, Manegold C, et al: Phase III clinical trial of gefitinib, an epidermal growth factor receptor inhibitor, in combination with gemcitibine and cisplatin in advanced non-small-cell lung cancer: INTACT 1. J Clin Oncol 22:777-784, 2004
17. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277:925-926, 1997
18. van Warmerdam LJ, Rodenhuis S, Ten Bokkel Huinink WW, et al: The use of the Calvert formula to determine the optimal carboplatin dosage. J Cancer Res Clin Oncol 121:478-486, 1995
19. Rom DM, Costello RJ, Connell LT: On closed test procedures for dose-response analysis. Stat Med 13:1583-1596, 1994
20. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
21. Goldman CK, Kim J, Wong WL, et al: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121-133, 1993
22. Ravindranath N, Wion D, Brachet P, et al: Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 22:432-443, 2001
23. Kataki A, Scheid P, Piet M, et al: Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med 140:320-328, 2002
24. Morikawa K, Walker SM, Nakajima M, et al: Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48:6863-6871, 1988
25. Inoue A, Saijo Y, Maemondo M, et al: Severe acute interstitial pneumonia and gefitinib. Lancet 361:137-139, 2003
26. Nicholson RI, Gee JMW, Harper ME: EGFR and cancer prognosis. Eur J Cancer 37:S9-15, 2001 (suppl 4)
27. Arteaga CL: Epidermal growth factor receptor dependence in human tumors: More than just expression? Oncologist 7:31-39, 2002 (suppl 4)
28. Meye A, Fiedler U, Kunert K, et al: Growth inhibitory effects of ZD1839 ('Iressa') on human bladder cancer cell lines. Proc Am Assoc Cancer Res 42:805, 2001 (abstr 4320)
29. Moasser MM, Basso A, Averbuch SD, et al: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61:7184-7188, 2001
30. Janmaat ML, Kruyt FAE, Rodriquez JA, et al: Inhibition of the epidermal growth factor receptor induces apoptosis in A431 cells, but not in non-small-cell lung cancer cell lines. Proc Am Assoc Cancer Res 43:XX, 2002 (abstr 3901)
31. Budillon A, Guarrasi R, Di Gennaro E, et al: ZD1839 ('Iressa'), an EGFR tyrosine kinase inhibitor, potentiates non-Mhc restricted cytotoxicity in human cancer cell lines. Proc Am Assoc Cancer Res 42:XX, 2001 (abstr 4306)
32. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001
33. Janas MS, Franklin WA, Schmidt K, et al: Interobserver reproducibility of visually interpreted EGFR immunohistochemical staining in non-small-cell lung cancer. Proc Am Assoc Cancer Res 44:XX, 2003 (abstr LB-213)
34. Bailey LR, Kris M, Wolf M, et al: Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pre-treated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 44:1362, 2003 (abstr LB-170)